Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

NCT03542110 is registered in ClinicalTrials.gov with Minneapolis Heart Institute Foundation as lead sponsor.

NCT NCT03542110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03542110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Lead sponsor
Minneapolis Heart Institute Foundation
Phase
Phase 4
Overall status
Terminated
Start date
August 4, 2018
Completion date
July 31, 2020
Enrollment
46 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

saphenous vein graft atherosclerosis